Sales exceed 30 million riyals during January.

Qatari Germany for Medical Devices Company (Q.P.S.C.) announces the completion of its

efforts towards profitability, which was noted through the financial results for the third.

quarter of 2020, where the company was able during January 2021 to obtain a number of

contracts and direct sales requests from the domestic and international market worth more

than 30 million riyals, which will reflect positively on the financial statements for the coming.

period.

Reduced operational and administrative expenses.

In order to apply the principle of disclosure and transparency to share the achievements

with the company's shareholders and investors to inform them of the company's efforts to

achieve its strategic objectives adopted by the Board of Directors headed by Mr. Saleh

Majed Al Khulaifi, which resulted in a reduction of its operating losses and administrative.

and general expenses by 35.89% in the third quarter of 2020 compared to the same

period of the previous year.

Opening new markets

The company was able to raise its production capacity to about 90% of the company’s.

capacity for the first time in its history, which prompted it to develop the quality of its

industry to compete strongly in the international markets that resulted in a number of

confirmed commercial transactions of medical syringes and the opening of new markets in

more than 10 countries worldwide, as the company is in the process of completing many.

commercial deals for the supply of syringes and export to more than 8 countries including.

Australia, Belgium, Britain, Germany, Iraq, South Africa, Mexico and Chile.

Participating in global tenders

The company has also entered international tenders such as the Baho Global Tender

and government-level tenders in Australia, Europe, Asia and Africa in order to ensure that.

syringes in all forms flow to these countries to contribute to the completion of vaccinations.

against the Covid-19 virus.

FDA approval

In addition, the company is now in the final stages of obtaining accreditation for our

products at the U.S. Drug and Food Administration (FDA) where it is one of the pillars of

our plans to expand our products and ease of adoption, which will contribute to the

opening of new markets.

Plant expansion plans

It is worth mentioning that the company is currently studying the extent of the possibility of

expanding the plant by adding additional production lines to be able to meet local and

international orders.

The efforts of the administrative and technical staff

On the increase in sales in the local market, the company praised the efforts of the

administrative and technical staff in the company to increase production capacity under

the exceptional conditions imposed by the Covid-19 virus pandemic and the difficulties in

entering and attracting skilled hands and the company gained the trust of Hamad Medical.

Corporation to be one of its main suppliers.

The demand for medical supplies is expected to increase locally and internationally, so the

company has studied the addition of new products to its product portfolio, which will be.

announced later, which will positively affect its financial results and increase sales volume.